Search Results - "Ullmann, C. Dansky"

Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer by Curti, B D, Ochoa, A C, Powers, G C, Kopp, W C, Alvord, W G, Janik, J E, Gause, B L, Dunn, B, Kopreski, M S, Fenton, R, Zea, A, Dansky-Ullmann, C, Strobl, S, Harvey, L, Nelson, E, Sznol, M, Longo, D L

“…We performed a phase I trial to determine whether in vivo expansion of activated CD4+ T cells was possible in cancer patients. 111Indium labeling was used to…”
Get more information

1308TiP - A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy by Annunziata, C., Dansky-Ullmann, C., Ghobadi, A., Weng, D., Vanas, J., Ekwede, I., Pavelova, M., Keefe, R., Kuo, M., Hassan, R., Thaker, P.

“…Chimeric antigen receptor (CAR) T cell therapy of solid tumors has not yet met the success seen in hematologic cancers. Many challenges include the antigen…”
Get full text

A phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy by Annunziata, C., Dansky-Ullmann, C., Ghobadi, A., Weng, D., Vanas, J., Ekwede, I., Pavelova, M., Keefe, R., Kuo, M., Hassan, R., Thaker, P.

Get full text

1308TiPA phase I study of intraperitoneal MCY-M11 Anti-mesothelin CAR for women with platinum resistant high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube, or subjects with peritoneal mesothelioma with recurrence after prior chemotherapy by Annunziata, C, Dansky-Ullmann, C, Ghobadi, A, Weng, D, Vanas, J, Ekwede, I, Pavelova, M, Keefe, R, Kuo, M, Hassan, R, Thaker, P

“…Abstract Background Chimeric antigen receptor (CAR) T cell therapy of solid tumors has not yet met the success seen in hematologic cancers. Many challenges…”
Get full text

Trial in Progress: Phase 3 Randomized Study of Investigational Drug Alisertib (Mln8237) Vs Investigator'S Choice in Patients (Pts) with Relapsed/Refractory (Rel/Ref) Peripheral T-Cell Lymphoma (Ptcl): the Lumiere Trial by Özcan, M., Shustov, A.R., Liu, H., Zhou, X., Dansky Ullmann, C., Kelly, V., Leonard, E.J., O'connor, O.

Get full text

876ORANDOMIZED PHASE 2 STUDY OF INVESTIGATIONAL, SELECTIVE AURORA A KINASE INHIBITOR ALISERTIB (MLN8237) WITH WEEKLY PACLITAXEL VS PACLITAXEL ALONE IN PATIENTS (PTS) WITH RECURRENT OVARIAN CANCER (OC) by Coleman, R., Roszak, A., Behbakht, K., Ray-Coquard, I.L., Matulonis, U., Liu, H., Schusterbauer, C., Ullmann, C. Dansky

“…Abstract Aim: Alisertib has shown modest single-agent activity in platinum-resistant OC and enhanced cytotoxicity with paclitaxel (P) preclinically. A phase 1…”
Get full text

Randomized Phase 2 Study of Investigational, Selective Aurora a Kinase Inhibitor Alisertib (Mln8237) with Weekly Paclitaxel Vs Paclitaxel Alone in Patients (Pts) with Recurrent Ovarian Cancer (Oc) by Coleman, R., Roszak, A., Behbakht, K., Ray-Coquard, I.L., Matulonis, U., Liu, H., Schusterbauer, C., Ullmann, C. Dansky

Get full text

985TiPTRIAL IN PROGRESS: PHASE 3 RANDOMIZED STUDY OF INVESTIGATIONAL DRUG ALISERTIB (MLN8237) VS INVESTIGATOR'S CHOICE IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (REL/REF) PERIPHERAL T-CELL LYMPHOMA (PTCL): THE LUMIERE TRIAL by Özcan, M., Shustov, A.R., Liu, H., Zhou, X., Dansky Ullmann, C., Kelly, V., Leonard, E.J., O'connor, O.

“…Abstract Background: PTCL is an aggressive form of non-Hodgkin lymphoma (NHL), accounting for 5–10% of NHL diagnoses. Standard NHL therapies developed…”
Get full text

Abstract PD5-5: Phase 2 study of single agent MLN8237 (alisertib), an investigational aurora A kinase (AAK) inhibitor, in patients (pts) with relapsed/refractory breast cancer (BrC) by Melichar, B, DeMichele, A, Adenis, A, Bourbouloux, E, Tan-Chiu, E, Niu, H, Schusterbauer, C, Dansky Ullmann, C, Zhang, B, Benaim, E

“…Background: AAK, a key mitotic regulator, is frequently amplified/overexpressed across a spectrum of tumors, including BrC. AAK overexpression is associated…”
Get full text

367 Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies by Zhou, X, Nemunaitis, J, Pant, S, Bauer, T.M, Patel, M, Sarantopoulos, J, Lockhart, A.C, Goodman, D, Zhang, B, Ullmann, C. Dansky, Mould, D.R, Venkatakrishnan, K

Get full text

Synergistic Effects of IL-6 and IFN-γ on Carcinoembryonic Antigen (CEA) and HLA Expression by Human Colorectal Carcinoma Cells: Role for Endogenous IFN-β by Dansky-Ullmann, Claudio, Salgaller, Michael, Adams, Sharon, Schlom, Jeffrey, Greiner, John W.

“…When administered as single agents, both interferon gamma (IFN-γ) and interleukin 6 (IL-6) significantly increase carcinoembryonic antigen (CEA) and HLA class…”
Get full text

Distribution, DNA damage and cytotoxic effects of etoposide in human tumor xenografts in vivo by Ullmann, C A, Eliot, H M, Sinha, B K

“…Mechanisms of resistance to VP-16 in vivo were studied using sensitive and multidrug resistant human breast tumor (MCF-7) cells, implanted bilaterally in nude…”
Get more information